Open Trials at Pacific Cancer Care

Available Clinical Trials at Pacific Cancer Care

Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.

For more information regarding clinical trial opportunities, please contact Monica Castillo, Clinical Research Manager, at mocastillo@pacificcancercare.com or call her at (831) 375-4105 ext. 1077

Multiple Myeloma
NCT# 02576977
KEYNOTE-183: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma

Multiple Myeloma
NCT# 02576977
KEYNOTE-185: A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma

Ovarian
NCT# 02855944
ARIAL-4: A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Squamous Non-Small Cell Lung Cancer
NCT# 02564380
KEYNOTE-407: A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-Small Cell Lung Cancer Subjects

Triple-Negative Breast Cancer
NCT# 02819518
KEYNOTE-355: A Randomized, Double-Blind Phase III Study of Pembrolizumab (MK-3475-KN355) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer

Triple-Negative Breast Cancer
NCT# 03036488
KEYNOTE-522: A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer
NCT# 01997333
METRIC – A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Blood Cancer Research Partnership with Dana-Farber Cancer Institute

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT# 02268851
A Multi-Center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies